Ahead of Suominen's Q2 report, we maintain our estimates intact.
The combination of ELEVIDYS from Sarepta and Imlifidase records early supportive top-line data for p...
Delays weigh down the quarter’s results.
Solwers’ Board of Directors has today appointed Johan Ehrnrooth as Solwers’ upcoming CEO and he will...
BeammWave has formalised its long-standing collaboration with Nitto Denko through a Joint Developmen...
Redeye comments on the partnership with SD Pharma in Spain, which will broaden physician reach of Pe...
Redeye comments on today’s news from Thunderful Group, which includes a SEK50m directed share issue,...
The delayed launch is a setback for both XVIVO, patients and specialist centers waiting to use the s...
Market environment has remained slow Etteplan released a profit warning due to persistently weak ma...
Redeye provides a short comment on the recently announced directed issue from Scandinavian ChemoTech...
Lower sales but demand for shore power solid Cavotec reported sales of EUR 36m (17% below our estima...
Some customers have postponed their orders due to uncertainties related to the US trade war.
Redeye makes rather small, but positive, changes to our financial forecasts on the back of strong Q2...
Redeye updates its forecast and valuation following Modelon’s Q2 2025 report, which came broadly in ...
Redeye comments on the outcome of AlzeCure’s rights issue, which was significantly oversubscribed at...
